Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Ophthalmology  |  Genetic Disease

Search Medical Condition
Please enter condition
Please choose location from dropdown

Macular Degeneration Clinical Trials

A listing of Macular Degeneration medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (164) clinical trials

Deficits Adaptation and Cerebral Functional Reorganization of Visual Retinotopic Treatments During Normal and Pathological Aging (Age-related Macular Degeneration and Glaucoma)

Healthy / control participants with normal vision will be volunteers, selected after interview (inclusion assessment). Their recruitment will be carried out on the basis of advertisements displayed at Grenoble Alpes University. Patients will be volunteers, selected on the basis of their ophthalmological clinical record. Their recruitment will be done at ...

Phase N/A

Stereotactic Radiotherapy for Wet AMD (STAR)

Age-related macular degeneration (AMD) leads more people to go blind than all other eye diseases combined. 'Wet' AMD occurs when abnormal new blood vessels grow into the macula. The macula is an area inside the back of the eye, which is tightly packed with the light-sensitive cells that give fine ...

Phase

The Focal Electro-Oculogram in Macular Disease

OBJECTIVE The objective of this protocol is to investigate the local response of the retinal pigment epithelium (RPE) across the posterior pole of the eye by recording the focal electrooculogram (EOG) in participants with macular disease. STUDY POPULATION: Up to 50 healthy volunteers and 80 participants, age 10 or older, ...

Phase N/A

Oxidative Stress In Stargardt Disease Age Related Macular Degeneration and Diabetic Retinopathy

People with Stargardt disease, age related macular degeneration (AMD) and diabetic retinopathy (DR) have decrease in central vision from damage to photoreceptors. One of the mechanisms causing damage is high levels of oxygen in the eye. This damage produces specific biomarkers that can be measured in eye fluid (aqueous humor). ...

Phase N/A

Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On

Objective: The overall objective of this extended follow-up study is to provide data regarding the incidence of late age-related macular degeneration (AMD), cataract surgery and lung cancer in the approximately 1,200 AREDS2 study participants enrolled in the Follow-on study. The specific objectives for the study are to: Study the rates ...

Phase N/A

A Phase 1b Dose Escalation Evaluation of Safety and Tolerability and a Phase 2 Proof of Concept Investigation of Efficacy and Safety of ASP7317 for Atrophy Secondary to Age-related Macular Degeneration

This is a two stage study followed by an extension stage. Stage 1 is a Phase 1b dose escalation evaluation of 3 doses of ASP7317; Stage 2 is Phase 2 Proof of Concept (PoC) investigation and Stage 3 is the extension stage which offers treatment options for participants randomized to ...

Phase

AMD Ryan Initiative Study (ARIS)

Objective Late age-related macular degeneration (AMD) is the leading cause of blindness among elderly in the United States. At present, the current classification systems do not take into consideration advances in imaging technology, visual function biomarkers, as well as genotyping and phenotyping. Clinical sites in the United States and around ...

Phase N/A

Open-Label Study of Intravitreal ICON-1 in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)

The purpose of this study is to evaluate the safety and effects of repeated intravitreal injections of ICON-1 0.6 mg administered as maintenance therapy or in combination with aflibercept in patients with wet macular degeneration.

Phase

Carbidopa-Levodopa in Dry AMD With Geographic Atrophy

Age-related macular degeneration (AMD) is the most common cause of blindness, in individuals over the age of 50, in the developed world. AMD becomes more common as people age, and is more common in lightly pigmented individuals. AMD appears more common in patients with Parkinson's Disease, than in those without. ...

Phase

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

This study will assess changes in complement factor B over a 69-week treatment period in a patient population 55 and older with well-demarcated Geographic Atrophy secondary to Age Related Macular Degeneration

Phase